Floatz logo

Mitoquinol mesilate

Fatigue

VA Office of Research and DevelopmentSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Fatigue cohort.

Asset / SponsorPhaseRating
Nuvastatic
Natureceuticals Sdn Bhd
Phase 3BB
Sra-333
Wake Forest University Health Sciences
Phase 2B
(D)-LIMONENE
Pure Green
Phase 2CCC
PALMITIC MONOETHANOLAMIDE
Pure Green
Phase 2CCC
Cediranib
City of Hope Medical Center
Phase 1CC

View all 12 →

Same molecule, other indications

Mitoquinol mesilate is also rated in:

mitochondrial diseaseDormant
B
Indicative ·
57 / 100
View asset →
schizophreniaDormant
B
Indicative ·
57 / 100
View asset →
amyotrophic lateral sclerosisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →